Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEDFIC 2 open-label extension of A4250 in children with PFIC type 1 or 2
MOH_2019-08-05_007329Phase 3Recruiting
- Sponsor
- Albireo Pharma
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of odevixibat in progressive familial intrahepatic cholestasis (PFIC) (2 cohorts), sponsored by Albireo Pharma. Started Nov 2018; status: recruiting.
02
Drugs
odevixibat
03
Conditions
progressive familial intrahepatic cholestasis (PFIC)
Beyond the preview
Go deeper on MOH_2019-08-05_007329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-08-05_007329.